2023-08-01 14:55:34
The World Health Organization (WHO) has included in the list of essential medicines the polypill developed by the National Center for Cardiovascular Research (CNIC) and the Ferrer laboratories that reduces mortality by 33% in patients treated after a heart attack.
Updated every two years, essential medicines lists are registries of medicines that the OMS it considers minimum requirements and that every health system must have available, the CNIC recalled in a note.
This cardiovascular polypill includes three active ingredients (acetylsalicylic acid, ramipril and atorvastatin) and generates higher levels of adherence than if the drugs were taken separately.
This drug has been shown to be effective in preventing cardiovascular events after a heart attack, decreasing mortality by 33%according to the Secure study published a year ago in The New England Journal of Medicine (NEJM).
“The results of SECURE revealed, for the first time, that the cardiovascular polypill developed by the CNIC and Ferrer achieves clinically relevant reductions in recurrent cardiovascular events in patients who have suffered a myocardial infarction,” he stresses. Valentín Fuster, principal investigator of the study and general director of the CNIC.
Currently, the polypill, which has evolved over the years, is marketed in 25 countries and the feasibility of expanding its distribution to other additional territories is being analyzed, among which the United States stands out.
Valentín Fuster during an interview with Efe/EFE/JP Gandul
Polipyldora: prevent recurrent cardiovascular events
The polypill “could become an integral part of strategies to prevent cardiovascular events in patients who have suffered a heart attack and who are currently being treated with the monocomponents separately,” says the cardiologist, also director of Mount Sinai Heart and medical director. from Mount Sinai Hospital in New York.
“This approach -he adds- has the potential to reduce the risk of recurrent disease and cardiovascular death.”
According to the doctor and researcher, as it is “a strategy that combines three of the baseline treatments in this type of patient”, this polypill “has demonstrated its value, since the increase in adherence means that patients are being treated for longer time and, thanks to this, they have a lower risk of suffering cardiovascular events”.
#Spanish #cardiovascular #polypill #essential #drug